Poziotinib Fails To Get FDA Panel Support Though Members Not As Dubious As Agency

Agency’s recent approval of Enhertu, which has better response rate, sways some panel members to vote against Spectrum’s NSCLC drug. FDA’s Pazdur compares poziotinib’s dosing uncertainty to ‘building a house on quicksand.’

Lung cancer
Spectrum's lung cancer drug fails to win backing of US FDA advisory committee • Source: Shutterstock

The majority of the US Food and Drug Administration’s Oncologic Drugs Advisory Committee agreed with the agency that the benefits of Spectrum Pharmaceuticals Inc.’s Pozenveo (poziotinib) for a rare form of lung cancer do not outweigh its risks, citing its lack of meaningful benefit over currently available therapies, uncertain dosing, and delay in initiation of a confirmatory trial.

But the 9-4 vote at the committee’s 22 September meeting shows that many members are willing to accept issues with...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers